Browse treatments

… dysregulation. Most patients with EC exhibit poor responses to immunotherapy, underscoring the need to identify novel therapeutic targets at…

… Systemic therapies for advanced gastric cancer (GC), including chemotherapy, targeted therapy and immunotherapy, have evolved significantly…

…se progression following treatments, including chemotherapy and immunotherapy. Initially hesitant to discuss end-of-life plans, the patient e…

…n to immune resistance and a promising target for combinatorial immunotherapy in PDAC.…

…zed cancers. URPS may serve as a novel biomarker for predicting immunotherapy response, with the potential to identify patients who are more …

…sion and seizures in our index case. The child was managed with immunotherapy and seizure control measures, showing significant clinical impr…

… dissection of intratumour heterogeneity in patients treated by immunotherapy, development of preclinical models that adequately capture hete…

…with immunotherapy and may be refractory to corticosteroids and biologic therapy. Evidence guiding management beyond anti-tumour necrosis factor…

…cisions about who should be allocated costly therapies, such as immunotherapy, which only work on a relatively low proportion of patients. In…

…osis of Lynch syndrome. This enabled the decision to treat with immunotherapy for recurrence and also conduct family screening. In spite of t…

…ptions and typically requires liver transplantation. In adults, immunotherapy is a promising treatment for HCC but there is limited understan…

…tial attention has been paid to innovations in early detection, immunotherapy and precision medicine, the programme’s administrative and oper…